The right diagnosis,
right away,
at the right price.

We are the creators of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. We have just obtained our CE-IVD Mark for the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX) which detects viruses and bacteria causing respiratory tract infections, the only solution of this kind in Europe. See more >>

News

2026.06.03

Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development

Company has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million. The proceeds will support the commercialization and strategic partnering of Genomtec’s proprietary diagnostic platforms, Genomtec ID® and OncoSNAAT®, while also accelerating the development of artificial […]

2026.05.19

Launch of the public offering of Genomtec shares to raise funds for the finalization of the M&A process and the commercialization of Genomtec ID and OncoSNAAT® technologies

Genontec S.A. announced the launch of a public offering of shares by its principal shareholder, 5HT Family Foundation, through an accelerated bookbuilding process (ABB). The proceeds from the offering will then be reinvested in the company’s balance sheet, as they will be fully reinvested in newly issued shares – 2 million new series R shares […]

2026.03.19

Genomtec plans to issue shares. The proceeds will be used to support the M&A process and commercialize projects. The company has concluded an investment agreement with a key shareholder.

Genomtec S.A. on April 13, 2026, at which the Shareholders will vote on an increase in the Company’s share capital through the issue of up to 2 million new series R shares and up to 204,000 series S shares, excluding pre-emptive rights. Genomtec intends to use the funds raised from the new share issue primarily […]

Awards